BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
Healthtrust
Accenture
Cantor Fitzgerald
McKinsey
Argus Health
Merck
Medtronic
Harvard Business School

Generated: January 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 9,180,096

« Back to Dashboard

Summary for Patent: 9,180,096
Title:Formulation of diclofenac
Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Inventor(s): Dodd; Aaron (Centennial Park, AU), Meiser; Felix (Mount Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H William (Bryn Mawr, PA)
Assignee: iCeutica Pty Ltd. (Philadelphia, PA)
Application Number:14/621,269
Patent Claims: 1. A solid oral unit dose of a pharmaceutical composition containing 18 mg of diclofenac acid, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 5000 nm, and wherein the unit dose, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37.degree. C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 75 minutes.

2. The unit dose of claim 1, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 3000 nm.

3. The unit dose of claim 2, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 60 minutes.

4. The unit dose of claim 2, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 45 minutes.

5. The unit dose of claim 2, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 30 minutes.

6. The unit dose of claim 1, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 2000 nm.

7. The unit dose of claim 6, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 60 minutes.

8. The unit dose of claim 6, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 45 minutes.

9. The unit dose of claim 6, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 30 minutes.

10. The unit dose of claim 1, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 1900 nm.

11. The unit dose of claim 1, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 1800 nm.

12. The unit dose of claim 1, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 60 minutes.

13. The unit dose of claim 1, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 45 minutes.

14. The unit dose of claim 1, wherein the unit dose has a dissolution rate of diclofenac acid such that 94%, by weight, is released by 30 minutes.

15. The unit dose of claim 1, wherein a single dose provides perceptible pain relief to a patient suffering from acute pain.

16. A solid oral unit dose of a pharmaceutical composition containing 35 mg of diclofenac acid, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 5000 nm, and wherein the unit dose, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37.degree. C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 75 minutes.

17. The unit dose of claim 16, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 3000 nm.

18. The unit dose of claim 17, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 60 minutes.

19. The unit dose of claim 17, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 45 minutes.

20. The unit dose of claim 17, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 30 minutes.

21. The unit dose of claim 16, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 2000 nm.

22. The unit dose of claim 21, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 60 minutes.

23. The unit dose of claim 21, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 45 minutes.

24. The unit dose of claim 21, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 30 minutes.

25. The unit dose of claim 16, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 1900 nm.

26. The unit dose of claim 16, wherein the D(90) of the diclofenac acid, on a particle volume basis, is less than 1800 nm.

27. The unit dose of claim 16, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 60 minutes.

28. The unit dose of claim 16, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 45 minutes.

29. The unit dose of claim 16, wherein the unit dose has a dissolution rate of diclofenac acid such that 95%, by weight, is released by 30 minutes.

30. The unit dose of claim 16, wherein a single dose provides perceptible pain relief to a patient suffering from acute pain.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Harvard Business School
Cerilliant
Farmers Insurance
Daiichi Sankyo
Fish and Richardson
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot